Terbinafine, a unique oral antifungal: Current perceptions

International Journal of Dermatology

Volumn 39, Issue 6, 2000, Pages 412-423

  Jain, Sanjeev ^b   Sehgal, Virendra N ^a  

^a Sehgal Nursing Home   (India)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ERGOSTEROL; ITRACONAZOLE; SQUALENE DERIVATIVE; TERBINAFINE;

ANTIFUNGAL ACTIVITY; CANDIDA; DOSE RESPONSE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG INHIBITION; DRUG SELECTIVITY; DRUG TISSUE LEVEL; HUMAN; MYCOSIS; ONYCHOMYCOSIS; REVIEW; SKIN DISEASE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTIFUNGAL AGENTS; CLINICAL TRIALS; FOOT DERMATOSES; HAND DERMATOSES; HUMANS; NAPHTHALENES; ONYCHOMYCOSIS;

EID: 0033927884     PISSN: 00119059     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-4362.2000.00978.x     Document Type: Review

References (72)

1. Pentranyi G, Ryder NS, Stuetz A. Allylamine derivatives: new class of synthetic antifungal agents inhibiting fungal squalene epoxidase. Science 1984; 224: 1239-1241.
2. Birnbaum JE, Pharmacology of the allylamines. J Am Acad Dermatol 1990; 23: 782-785.
3. Villars VV, Jones TC. Clinical efficacy and tolerability of terbinafine (Lamisil) - a new topical and systemic fungicidal drug for the treatment of dermatomycoses. Clin Exp Dermatol 1989; 14: 124-127.
4. Villars V, Jones TC. Special features of the clinical use of terbinafine in the treatment of fungal diseases. Br J Dermatol 1992; 126: 61-69.
5. Shear NH, Gupta AK. Terbinafine for the treatment of pedal onychomycosis: a foot closer to the promised land of cured nails? Arch Dermatol 1995; 131: 937-942.
6. Ryder NS, Dupon MC. Inhibition of squalene epoxidase by allylamine antimycotic compounds: a comparative study of the fungal and mammalian enzymes. Biochem J 1985; 230: 765-770.
7. Shadomy S, Espinell-Ingroff A, Gebhart RJ. In vitro studies with SF 86-327, a new orally active allylamine derivative. Sabouraudia 1985; 23: 125-132.
8. Petranyi G, Meingassner JG, Mieeth H. Antifungal activity of the allylamine derivative terbinafine in vitro. Antimicrob Agents Chemother 1987; 31: 1365-1368.
9. Ahmad A, Khan AK, Sultana S, et al. Ini vitro antifungal studies of terbinafine. Pakistan J Sci Ind Res 1989; 32: 737-739.
10. Hiratani T, Asagi Y, Yamaguchi H. Evaluation of in vitro antimycotic activity of terbinafine, a new allylamine agent. Jpn J Med Mycol 1991; 32: 323-332.
11. Rubio MC, Gil J, Rezusta A, et al. In vitro evaluation of three new antifungal agents; amovolfine (Ro 14-4767/ 002), terbinafine (SF 86-327) and itraconazole (R51, 221). Rev Esp Quimioterap 1993; 6: 125-139.
12. Venugopal PV, Venugopal TV. Antidermatophytic activity of allylamine derivatives. Int J Pathol Microbiol 1994; 37: 381-388.
13. Venugopal PV, Venugopal TV. Antifungal activity of allylamine derivatives. Ind J Med Res 1994; 99: 71-73.
14. Korting HC, Ollert M, Abech D, et al. Results of German multicentre study of antimicrobial susceptibilities of Trichophyton rubrum and Trichophyton mentagrophytes strains causing tinea unguium. Antimicrob Agents Chemother 1995; 39: 1206-1208.
15. Butty P, Lobecq JC, Mallie M, Bastide JM. Evaluation of the susceptibility of dermatophytes to antifungal drugs; a new technique. J Med Vet Mycol 1995; 33: 403-409.
16. Clayton YM. Relevance of broad-spectrum and fungicidal activity of antifungals in the treatment of dermatomycoses. Br J Dermatol 1994; 130 (Suppl. 43): 7-8.
17. Hazen KC. Fungicidal versus fungistatic activity of terbinafine and itraconazole: an in vitro comparison. J Am Acad Dermatol 1998; 38: 537-541.
18. Weitzmen I, Summerbell RC. The dermatophytes. Clin Microbiol Rev 1995; 8: 240-259.
19. Schauden M, Ackerbraver H, Mieth H. Inhibitory effect of antifungal agents on germ tube formation in Candida albicans. Mykosen 1987; 30: 281-287.
20. Ryder NS, Wagner S, Leitner T. In vitro activity of terbinafine against Candida and other yeasts by NCCLS method. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Washington DC, 15-18 September 1991. 1991; Abstract E55: 91.
21. Kagawa S. Clinical efficacy of terbinafine in 619 Japanese patients with dermatomycoses. Clin Exp Dermatol 1989; 14: 114-115.
22. Jung EG, Haas PJ, Brautigam H, et al. Systemic treatment of skin candidosis: randomized comparison of terbinafine and ketoconazole. Mycoses 1994; 37: 361-365.
23. Speeleveld E, Gordts V, Van Landuyt HW, et al. Susceptibility of clinical isolates of Fusarium to antifungal drug. Mycoses 1996; 30: 37-40.
24. Favre B, Ryder NS. Characterization of squalene epoxidase activity from the dermatophyte Trichophyton rubrum and its inhibition by terbinafine and other antimycotic agents. Antimicrob Agents Chemother 1996; 40: 443-447.
25. Gnamusch E, Ryder NS, Paltauf F. Effect of squalene on the structure and functions of fungal membranes. J Dermatol Treat 1992; 3 (Suppl.): 9-13.
26. Ryder NS. Terbinafine: mode of action and properties of the squalene epoxidase inhibition. Br J Dermatol 1991; 126 (Suppl. 39): 2-7.
27. Ryder NS. Specific inhibition of fungal sterol biosynthesis by SF 86-327, a new allylamine antimycotic agent. Antimicrob Agents Chemother 1985; 27: 252-256.
28. Schuster T. The interaction of representative members from two classes of antimycotic, the azole and the allylamines, with cytochrome P 450 in steroidogenic tissues and liver. Xenobiotics 1985; 15: 529-546.
29. Schuster T, Schaide M, Schatz F, Mieth H. Preclinical characteristic of allylamines. In: Berg D, Plempel M, eds. Sterol Biosynthesis Inhibitors: Pharmaceutical and Agrochemical Aspects. Chichester: Ellis Horwood; Weinheim: Verlagagesellschapt mb H Publishers, 1988: 439-470.
30. Brodell RT, Elewski BE. Clinical pearl: systemic antifungal drugs and drug interactions. J Am Acad Dermatol 1995; 33: 259-260.
31. Jensen JC. Clinical pharmacokinetics of terbinafine (Lamisil). Clin Exp Dermatol 1989; 14: 110-113.
32. Stephen A, Czok R, Male O. Terbinafine; initial clinical results. In: Formiling RA, ed. Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents. Barcelona: J.R. Prous Science Publishers, 1987: 511-520.
33. Jansen JC. Pharmacokinetics of Lamisil in humans. J Dermatol Treat 1990; 1 (Suppl. 2): 15-18.
34. Faergemann J, Zehender H, Jones T, et al. Terbinafine levels in serum, stratum corneum, dermis-epidermis (without stratum corneum), hair, sebum, and eccrine sweat. Acta Derm Venereol (Stockh) 1990; 70: 322-326.
35. Faergemann J, Zehender H, Jones T, et al Terbinafine levels in serum, stratum corneum, dermis-epidermis (without stratum corneum), hair, sebum, and eccrine sweat. Acta Derm Venereol 1991; 71: 322-326.
36. Faergemann J, Zehender D, Denouël J, et al. Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once per day for four weeks. Acta Derm Venereol (Stockh) 1993; 73: 305-309.
37. Faergemann J, Zehender H, Milleroux L. Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once daily for 7 and 14 days. Clin Exp Dermatol 1994; 19: 121-126.
38. Faergemann J, Zehender H, Boukhabza A, et al. Comparison of terbinafine levels in stratum corneum and dermis-epidermis (without stratum corneum) after topical or topical combined with oral therapy in healthy volunteers. J Eur Acad Dermatol Venereol 1995; 5 (Suppl. 1): 594.
39. Lever LR, Dyties PJ, Thomas R, et al. How orally administered terbinafine reaches the stratum corneum. J Dermatol Treat 1990; 1 (Suppl. 2): 23-25.
40. Faergemann J, Zehender H, Boukhabza A, et al. A double-blind comparison of levels of terbinafine and itraconazole in plasma, skin, sebum, hairs and nails during and after oral medication. Acta Derm Venereol (Stockh) 1997; 77: 74-76.
41. Finlay AY. Pharmacokinetics of terbinafine in the nail. Br J Dermatol 1992; 126 (Suppl. 39): 28-32.
42. Finlay AY, Level L, Thomas R, et al. Nail matrix of oral terbinafine in onychomycosis and normal nails. J Dermatol Treat 1990; 1 (Suppl. 2): 51-53.
43. Finlay AY. Pharmacokinetics of terbinafine in the nail. J Dermatol Treat 1992; 3 (Suppl. 1): 15-17.
44. Schatz F, Brautigam M, Dobrowolski E, et al. Nail incorporation kinetics of terbinafine in onychomycosis patients. Clin Exp Dermatol 1995; 20: 377-383.
45. Zehender H, Cabiac MD, Denouel J, et al. Elimination kinetics of terbinafine from human plasma and tissues following multiple dose administration, and comparison with 3 main metabolites. Drug Invest 1994; 8: 203-210.
46. Kovarik JM, Mieller EA, Zehender H, et al. Multiple dose pharmacokinetics and distribution in tissue of terbinafine and metabolites. Antimicrob Agents Chemother 1995; 39: 2738-2741.
47. Zaias N, Serrano L. The successful treatment of finger Trichophyton rubrum onychomycosis with oral terbinafine. Clin Exp Dermatol 1989; 14: 120-123.
48. Goodfield MJ, Rowell NR, Forster RA, et al. Treatment of dermatophyte infection of the finger and toenails w/o terhinafine (SF 86-327, Lamisil), an orally active fungicidal agent. Br J Dermatol 1989; 121: 353-357.
49. Allen BR, Cocoley N, Dawher R, et al. Oral terbinafine effective in the treatment of chronic nail dermatophytosis. Br J Dermatol 1989; 121 (Suppl. 34): 16.
50. Lacosi T. Terbinafine and onychomycosis. Dermatologica 1990; 181: 174
51. Goodfield MJD. Clinical results with terhinafine in onychomycosis. J Dermatol Treat 1990; 1 (Suppl. 2): S57-67.
52. Baudraz Rosselet F, Rakosi T, et al. Treatment of onychomycosis with terbinafine. Br J Dermatol 1992; 126 (Suppl. 39): 40-46.
53. Van der Schroeff JG, Cirkel PKS, Crijus MD, et al. A randomized treatment duration finding study of terhinafine in onychomycosis. Br J Dermatol 1992; 126 (Suppl. 39): 36-39.
54. Giber B, Gosshans E. Efficacie et tolerance de la terbinafine (Lamisil) dans line serie de 50 onychomycosis a dermatophytes. Ann Dermatol Venereol 1994; 121: 15-20.
55. Galimberte R, Kowalezyk A, Flores V, et al. Onychomycosis treated with a short course of oral terbinafine. Int J Dermatol 1996; 35: 374-375.
56. Tausch I, Prantigam M, Weidringer G, et al. Evaluation of six weeks treatment of terbinafine in tinea unguium in a double blind trial comparing 6 and 12 weeks therapy. The Lagos V Study Group. Br J Dermatol 1997; 136: 737-742.
57. Waston AB, Harley JE, Ellis DLL, et al. Long term follow up of patients with toenail onychomycosis after treatment with terbinafine. Australas J Dermatol 1998; 39: 29-30.
58. Goodfield MJD. Short duration therapy with terhinafine for dermatophyte onychomycosis: a multicentre trial. Br J Dermatol 1992; 126 (Suppl. 39): 33-35.
59. Watson A, Marley J, Ellis D, et al. Terbinafine in onychomycosis of the toe nail: a novel treatment protocol. J Am Acad Dermatol 1995; 33: 775-779.
60. Svejgaarel EL, Brandrup F, Kragballe K, et al. Oral terbinafine in toenail dermatophytes. A double-blind, placebo-controlled multicentre study with 12 months follow-up. Acta Derm Venereol 1997; 77: 66-69.
61. Drake LA, Shear NH, Arlette JP, et al. Oral terbinafine in the treatment of toenail onychomycosis: North American multicenter trial. J Am Acad Dermatol 1997; 37: 740-745.
62. Faergemann J, Anderson C, Hersek K, et al. Double blind, parallel group comparison of terbinafine and griseofulvin in the treatment of toe nail onychomycosis. J Am Acad Dermatol 1995; 32: 750-753.
63. Haneke E, Tausch T, Brautigam M, et al. Short duration treatment of fingernail dermatophytosis: a randomized double blind study with terbinafine and griseofulvin. J Am Acad Dermatol 1995; 32: 72-77.
64. Hoffmann H, Brautigan M, Weidinger G, et al. Treatment of toe nail onychomycosis: a randomized, double blind study with terbinafine and griseofulvin. Arch Dermatol 1995; 131: 919-911.
65. Arenas R, Dominguez-Cherit J, Fernandez LM. Open randomized comparison of itraconazole versus terbinafine in onychomycosis. Int J Dermatol 1993; 34: 138-143.
66. Brautigam M, Nolting S, Schopf RE, et al. Randomized double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. Br Med J 1995; 311: 919-922.
67. Roberts DT, Richardson MD, Dwyer PK. Terhinafine in chronic paronychia and Candida onychomycosis. J Dermatol Treat 1992; 3 (Suppl): 39-42.
68. Cox NH, Irving B. Cutaneous 'ringworm' lesions of Scopulariopsis brevicaulis. Br J Dermatol 1993; 129.
69. Segal R, Giadelli L, Kritzman A, et al. Treatment of Candida nail infection with terbinafine. 2nd International Summit on Cutaneous Antifungal Therapy, Boston, Massachusetts, November 10-13, 1994.
70. Nolting S, Brautigam M, Weidinger G. Terbinafine in onychomycosis with involvement by non-dermatophyte fungi. Br J Dermatol 1994; 130 (Suppl. 43): 16-21.
71. Wong CK, Cho YL. Very short duration therapy with oral terbinafine for fingernail onychomycosis. Br J Dermatol 1995; 133: 329-347.
72. Tosti A, Piarccini EM, Stinchi C, Loronzi S. Onychomycosis due to Scopulariopsis brevicaulis: clinical features and response to systemic anti-fungals. Br J Dermatol 1996; 135: 799-802.